Search research articles
Contact Us
Filters
Showing results (101-110 of 112) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial
Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
The Lancet. Oncology
|
March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
BMC Cancer
|
November 26, 2014
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial)
Antonio Avallone, Maria Carmela Piccirillo, Paolo Delrio, et al.
Gynecologic Oncology
|
April 14, 2019
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
Sandro Pignata, Giovanni Scambia, Domenica Lorusso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 6, 2022
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 1, 2021
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, et al.
BMC Cancer
|
February 10, 2016
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)
Antonio Avallone, Maria Carmela Piccirillo, Luigi Aloj, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2019
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial
Francesco Perrone, Michelino De Laurentiis, Sabino De Placido, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 31, 2021
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial
Raimondo Di Liello, Laura Arenare, Francesco Raspagliesi, et al.
Journal of Translational Medicine
|
October 22, 2021
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 112) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial
Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
The Lancet. Oncology
|
March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
BMC Cancer
|
November 26, 2014
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial)
Antonio Avallone, Maria Carmela Piccirillo, Paolo Delrio, et al.
Gynecologic Oncology
|
April 14, 2019
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
Sandro Pignata, Giovanni Scambia, Domenica Lorusso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 6, 2022
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 1, 2021
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, et al.
BMC Cancer
|
February 10, 2016
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)
Antonio Avallone, Maria Carmela Piccirillo, Luigi Aloj, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2019
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial
Francesco Perrone, Michelino De Laurentiis, Sabino De Placido, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 31, 2021
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial
Raimondo Di Liello, Laura Arenare, Francesco Raspagliesi, et al.
Journal of Translational Medicine
|
October 22, 2021
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, et al.
Page
of 12